86.335  -2.905 (-3.26%)		08-28 16:00
Open: 88.79 High: 89.65 Volume: 435,131		Pre. Close: 89.24 Low: 85.925 Market Cap: 2,575(M)

Short term
Mid term
Targets	6-month :	107.19	1-year :	125.2
Resists	First :	91.77	Second :	107.19
Pivot price	82.71
Supports	First :	71.55	Second :	59.04
MAs	MA(5) :	87.69	MA(20) :	79.8
	MA(100) :	62.73	MA(250) :	93.92
MACD	MACD :	5.6	Signal :	5
%K %D	K(14,3) :	84.9	D(3) :	91.7
RSI	RSI(14): 63.5
52-week	High :	170.86	Low :	32.2

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ WGS ] has closed below upper band by 29.7%. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	89.69 - 90.29	90.29 - 90.79
Low:	84.79 - 85.37	85.37 - 85.85
Close:	85.49 - 86.43	86.43 - 87.2

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Thu, 27 Aug 2026
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Wed, 26 Aug 2026
GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells Investors - GuruFocus

Tue, 25 Aug 2026
WGS Stock Slumps After Hours As Firm Predicts Lower Test Volume For Year - Stocktwits

Tue, 25 Aug 2026
GeneDx Holdings (WGS) Study Data Puts Its Fair Value Debate Back In Focus - Sahm

Mon, 24 Aug 2026
A GeneDx study found genetic diagnoses in 63% of children with faltering growth - Stock Titan

Tue, 18 Aug 2026
GeneDx: Why I Think The Worst Is Behind The Business (NASDAQ:WGS) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	30 (M)
Shares Float	20 (M)
Held by Insiders	12.2 (%)
Held by Institutions	107.6 (%)
Shares Short	5,850 (K)
Shares Short P.Month	5,940 (K)

EPS	-3.64
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	8.56
Profit Margin	-23.5 %
Operating Margin	-15.3 %
Return on Assets (ttm)	-7.9 %
Return on Equity (ttm)	-40.8 %
Qtrly Rev. Growth	11.3 %
Gross Profit (p.s.)	10.57
Sales Per Share	15.23
EBITDA (p.s.)	-1.14
Qtrly Earnings Growth	0 %
Operating Cash Flow	-49 (M)
Levered Free Cash Flow	-48 (M)

PE Ratio	-23.79
PEG Ratio	0
Price to Book value	10.07
Price to Sales	5.66
Price to Cash Flow	-52.86

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.